

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Guanze Medical Information Industry (Holding) Co., Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock code : 2427)

PROFIT WARNING

This announcement is made by Guanze Medical Information Industry (Holding) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2024 and the information currently available, it is expected that the Group will record a loss attributable to owners of the Company of not more than RMB1.0 million for the six months ended 30 June 2024 as compared to the profit attributable to owners of the Company of approximately RMB15.9 million for the six months ended 30 June 2023. The Board considers that the expected loss was primarily attributable to the decrease in revenue of approximately RMB34.4 million as a result of the decrease in average selling price and the volume of the medical imaging films sold.

The Company is still in the process of finalising the interim results of the Group for the six months ended 30 June 2024. The information contained in this announcement is only based on the preliminary assessment by the Board with reference to the information currently available to the Group and the unaudited consolidated management accounts of the Group for the six months ended 30 June 2024, which has not been audited or reviewed by the auditors or the audit committee of the Company and may be subject to adjustments. The Shareholders and potential investors are advised to read carefully the interim results announcement of the Company for the six months ended 30 June 2024, which is expected to be published by the end of August 2024.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Guanze Medical Information Industry (Holding) Co., Ltd.
Meng Xianzhen
Chairman of the Board

Hong Kong, 16 August 2024

As at the date of this announcement, the Board comprises Mr. Meng Xianzhen and Mr. Guo Zhenyu as executive directors; Ms. Meng Cathy as non-executive director; and Dr. Zhao Bin, Dr. Chang Shiwang and Dr. Wong Man Hin Raymond as independent non-executive directors.